Bader, Jackie E.
Wolf, Melissa M.
Lupica-Tondo, Gian Luca http://orcid.org/0000-0002-4237-0750
Madden, Matthew Z. http://orcid.org/0000-0003-4062-4427
Reinfeld, Bradley I. http://orcid.org/0000-0003-4161-8301
Arner, Emily N. http://orcid.org/0000-0003-3589-8829
Hathaway, Emma S.
Steiner, KayLee K. http://orcid.org/0000-0003-2188-6376
Needle, Gabriel A. http://orcid.org/0000-0002-8092-1074
Hatem, Zaid
Landis, Madelyn D.
Faneuff, Eden E.
Blackman, Amondrea
Wolf, Elysa M.
Cottam, Matthew A.
Ye, Xiang http://orcid.org/0000-0002-8694-8710
Bates, Madison E.
Smart, Kyra
Wang, Wenjun http://orcid.org/0000-0003-0907-6282
Pinheiro, Laura V.
Christofides, Anthos
Smith, DuPreez
Boussiotis, Vassiliki A. http://orcid.org/0000-0002-3963-1518
Haake, Scott M. http://orcid.org/0000-0003-3455-0791
Beckermann, Kathryn E. http://orcid.org/0000-0002-4616-6140
Wellen, Kathryn E. http://orcid.org/0000-0002-2281-0042
Reinhart-King, Cynthia A. http://orcid.org/0000-0001-6959-3914
Serezani, C. Henrique
Lee, Cheng-Han
Aubrey, Christa
Chen, Heidi
Rathmell, W. Kimryn
Hasty, Alyssa H. http://orcid.org/0000-0001-7302-8045
Rathmell, Jeffrey C. http://orcid.org/0000-0002-4106-3396
Article History
Received: 4 November 2022
Accepted: 7 May 2024
First Online: 12 June 2024
Change Date: 9 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-024-07794-2
Competing interests
: J.C.R. has held stock equity in Sitryx and in the past two years has received unrelated research support, travel and honoraria from Sitryx, Caribou, Nirogy, Kadmon, Calithera, Tempest, Merck, Mitobridge and Pfizer. In the past two years, W.K.R. has received unrelated clinical research support from Bristol-Meyers Squib, Merck, Pfizer, Peloton, Calithera and Incyte. Both J.C.R. and W.K.R. are divested of these interests at present. K.E.B. received funding to the institution for preclinical research from Bristol-Myers Squibb–International Association for the Study of Lung Cancer–Lung Cancer Foundation of America, funding to the institution for clinical trials from Arrowhead, Aravive, Aveo, BMS, Exelexis and Merck, and consulting fees from Alpine Immune Sciences, Aravive, AstraZeneca, Aveo, BMS, Exelexis, Merck, Seagen and Sanofi. V.A.B. has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako.